Doximity (DOCS) Earnings: Q2 Fiscal 2027 Results and Next Report Date

The quarter ended September 30, 2026 and Doximity published the results on November 5, 2026. Revenue and diluted EPS are shown against Q2 fiscal 2026, the same quarter a year earlier, which takes seasonal swings out of the comparison. Doximity reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP diluted net income per share, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Doximity's fiscal year ends March 31, so Q2 fiscal 2027 is the quarter ended September 30, 2026. Doximity reports in thousands; figures here are in millions.
• Doximity reports revenue as one figure with no segment split. About 93% of Q2 fiscal 2027 revenue came from subscription customers.

Source: Doximity Q2 fiscal 2027 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

From the earnings release

The first two lines are Doximity's guidance for Q3 fiscal 2027, the quarter ending December 31, 2026. The last two are its updated guidance for fiscal 2027, ending March 31, 2027.

In its Q2 fiscal 2027 release, Doximity said:

“Revenue between $195 million and $196 million.”

“Adjusted EBITDA between $102.5 million and $103.5 million.”

“Revenue between $678 million and $683 million.”

“Adjusted EBITDA between $317 million and $325 million.”

Source: Doximity Q2 fiscal 2027 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the DOCS forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release.

Doximity's next report is expected around February 4, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q2 fiscal 2027 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q2 fiscal 2027 (this page), reported Nov 5, 2026

Doximity's revenue was $174.5 million in Q2 fiscal 2027, up 4% from $168.5 million. Doximity sells Marketing, Hiring and Workflow Solutions to customers that are mainly pharmaceutical manufacturers and health systems, built on a network whose members include more than 85% of U.S. physicians. (Doximity Q2 fiscal 2027 release, Nov 5, 2026; Doximity Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

About 93% of Doximity's Q2 fiscal 2027 revenue came from subscription customers. Revenue rose $6.0 million, of which $3.1 million was subscription revenue, mainly from new subscription customers. Most of the rest of the increase came from temporary staffing and permanent placement revenue. (Doximity Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Doximity's large customers dominate its revenue. Customers with at least $500,000 of trailing 12-month subscription revenue numbered 124, against 120 a year earlier, and accounted for about 82% of revenue for the 12 months to September 30, 2026. One customer accounted for 10% or more of total revenue in fiscal 2026, and some customers buy through marketing agencies. (Doximity Form 10-Q, Q2 fiscal 2027, Nov 5, 2026; Doximity Form 10-K, fiscal 2026, May 19, 2026)

Net revenue retention slowed to 103% from 118% a year earlier. Doximity says the rate is directly tied to its revenue growth rate. Usage kept rising: quarterly unique active providers using its workflow tools grew about 34% year over year, which Doximity links in part to its AI suite. (Doximity Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Doximity's GAAP diluted EPS fell to $0.18 in Q2 fiscal 2027 from $0.31, and net income to $34.7 million from $62.1 million. Income from operations dropped to $43.9 million from $63.7 million as research and development rose $11.8 million and cost of revenue $8.9 million, the latter mainly from hosting and software costs for its AI initiatives. (Doximity Q2 fiscal 2027 release, Nov 5, 2026; Doximity Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Non-GAAP diluted EPS of $0.36 excludes stock-based compensation, which rose to $40.6 million from $29.5 million, along with amortization of acquired intangibles and certain legal and acquisition costs, adjusted for tax. The effective tax rate was 31.0%, against 14.9% a year earlier. (Doximity Q2 fiscal 2027 release, Nov 5, 2026; Doximity Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Buybacks cut Doximity's share count. Diluted weighted-average shares were 187,804 thousand, against 200,745 thousand. Doximity spent $54.2 million on repurchases in the quarter, and $346.7 million remained under its February 2026 program at September 30, 2026. (Doximity Q2 fiscal 2027 release, Nov 5, 2026; Doximity Form 10-Q, Q2 fiscal 2027, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Doximity gives a next-quarter and full-year outlook in its release. For Q3 fiscal 2027, the quarter ending December 31, 2026, it guided revenue between $195 million and $196 million and Adjusted EBITDA between $102.5 million and $103.5 million. (Doximity Q2 fiscal 2027 release, Nov 5, 2026)

For fiscal 2027, ending March 31, 2027, Doximity updated guidance to revenue between $678 million and $683 million and Adjusted EBITDA between $317 million and $325 million. Further modeling detail is in prepared remarks posted on its investor relations website. (Doximity Q2 fiscal 2027 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Doximity, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Doximity's own release and filings put weight on for Q2 fiscal 2027, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning DOCS is on is DOCS a buy or a sell?, what analysts expect next is on the DOCS forecast, and what the company does is on the Doximity (DOCS) stock page.

Every number on this page can be traced to a document Doximity published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.